5-Cyano-5-[5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-Cyano-5-[5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
• 化学式: C₂₂H₃₃NO₅
• 分子量: 391.5
• InChiKey: OJIGXQJDLFUVFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS
  申请人：Gemmus Pharma Inc.

  公开号：EP2488168A1

  公开（公告）日：2012-08-22
• [EN] COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS<br/>[FR] TRAITEMENT PAR POLYTHÉRAPIE POUR INFECTIONS VIRALES
  申请人：GEMMUS PHARMA INC

  公开号：WO2011047048A1

  公开（公告）日：2011-04-21

  Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, "SARS".
• [EN] COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS<br/>[FR] POLYTHÉRAPIE D'ANTIBIOTIQUES ET D'AGONISTES GPCR POUR CO-INFECTIONS VIRALES/BACTÉRIENNES
  申请人：GEMMUS PHARMA INC

  公开号：WO2015109112A1

  公开（公告）日：2015-07-23

  Agonists of the GPCR receptors are useful as therapeutics for the treatment of viral infections. Agonists are used alone or in combination with antibiotics to treat an active viral infection with a secondary bacterial infection or prophylactically treat a patient, for example, a patient currently having a viral infection.